Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update.</li><li>The company is on track to initiate the confirmatory Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of patients with early stage cutaneous T cell lymphoma (CTCL) in the second half of 2025.</li><li>In support of this, the company recently announced positive clinical results from a comparability study between HyBryte and Valchlor , which showed a three-fold higher response rate over a 12-week treatment period and a more favorable safety profile for HyBryte.</li></ul>

On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update.The company is on track to initiate the confirmatory Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of patients with early stage cutaneous T cell lymphoma (CTCL) in the second half of 2025.In support of this, the company recently announced positive clinical results from a comparability study between HyBryte and Valchlor , which showed a three-fold higher response rate over a 12-week treatment period and a more favorable safety profile for HyBryte.

SNGX: Phase 3 Trial of HyBryte  in CTCL to Initiate in 2H24 